AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy

Journal of Experimental Medicine

Volumn 214, Issue 5, 2017, Pages 1227-1238

  Ising, Christina ^a   Gallardo, Gilbert ^a   Leyns, Cheryl E G ^a   Wong, Connie H ^a   Jiang, Hong ^a   Stewart, Floy ^a   Koscal, Lauren J ^a   Roh, Joseph ^a   Robinson, Grace O ^a   Serrano, Javier Remolina ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TAU PROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; TAUOPATHY; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BRAIN; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE TRANSFER; GENETICS; HIPPOCAMPUS; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; BRAIN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENE TRANSFER TECHNIQUES; HIPPOCAMPUS; MALE; MICE; MICE, TRANSGENIC; SINGLE-CHAIN ANTIBODIES; TAU PROTEINS; TAUOPATHIES;

EID: 85021855424     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20162125     Document Type: Article

References (39)

1. Adolfsson, O., M. Pihlgren, N. Toni, Y. Varisco, A.L. Buccarello, K. Antoniello, S. Lohmann, K. Piorkowska, V. Gafner, J.K. Atwal, et al. 2012. An effector-reduced anti-β-amyloid (Aβ) antibody with unique αβ binding properties promotes neuroprotection and glial engulfment of Aβ. J. Neurosci. 32:9677-9689. http ://dx .doi .org/10 .1523/JNE URO SCI .4742-11 .2012
2. Ahmad, Z.A., S.K. Yeap, A.M. Ali, W.Y. Ho, N.B.M. Alitheen, and M. Hamid. 2012. scFv antibody: Principles and clinical application. Clin. Dev. Immunol. 2012:980250. http ://dx .doi .org/10 .1155/2012/980250
3. Ahmed, Z., J. Cooper, T.K. Murray, K. Garn, E. McNaughton, H. Clarke, S. Parhizkar, M.A. Ward, A. Cavallini, S. Jackson, et al. 2014. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: The pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 127:667-683. http ://dx .doi .org/10 .1007/s00401-014-1254-6
4. Asai, H., S. Ikezu, S. Tsunoda, M. Medalla, J. Luebke, T. Haydar, B. Wolozin, O. Butovsky, S. Kügler, and T. Ikezu. 2015. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat. Neurosci. 18:1584-1593. http ://dx .doi .org/10 .1038/nn .4132
5. Beaudoin, G.M.J. III, S.-H. Lee, D. Singh, Y. Yuan, Y.-G. Ng, L.F. Reichardt, and J. Arikkath. 2012. Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. Nat. Protoc. 7:1741-1754. http ://dx .doi .org/10 .1038/nprot .2012 .099
6. Boutajangout, A., J. Ingadottir, P. Davies, and E.M. Sigurdsson. 2011. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118:658-667. http ://dx .doi .org/10 .1111/j .1471-4159 .2011 .07337 .x
7. Brier, M.R., B. Gordon, K. Friedrichsen, J. McCarthy, A. Stern, J. Christensen, C. Owen, P. Aldea, Y. Su, J. Hassenstab, et al. 2016. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease. Sci. Transl. Med. 8:338ra66. http ://dx .doi .org/10 .1126/scitranslmed .aaf2362
8. Castillo-Carranza, D.L., M.J. Guerrero-Muñoz, U. Sengupta, C. Hernandez, A.D.T. Barrett, K. Dineley, and R. Kayed. 2015. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. J. Neurosci. 35:4857-4868. http ://dx .doi .org/10 .1523/JNE URO SCI .4989-14 .2015
9. Chai, X., S. Wu, T.K. Murray, R. Kinley, C.V. Cella, H. Sims, N. Buckner, J. Hanmer, P. Davies, M.J. O'Neill, et al. 2011. Passive immunization with anti-Tau antibodies in two transgenic models: Reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 286:34457-34467. http ://dx .doi .org/10 .1074/jbc .M111 .229633
10. Chakrabarty, P., A. Rosario, P. Cruz, Z. Siemienski, C. Ceballos-Diaz, K. Crosby, K. Jansen, D.R. Borchelt, J.-Y. Kim, J.L. Jankowsky, et al. 2013. Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS One. 8:e67680. http ://dx .doi .org/10 .1371/journal .pone .0067680
11. Clavaguera, F., J. Hench, M. Goedert, and M. Tolnay. 2015. Invited review: Prion-like transmission and spreading of tau pathology. Neuropathol. Appl. Neurobiol. 41:47-58. http ://dx .doi .org/10 .1111/nan .12197
12. d'Abramo, C., C.M. Acker, H.T. Jimenez, and P. Davies. 2013. Tau passive immunotherapy in mutant P301L mice: Antibody affinity versus specificity. PLoS One. 8:e62402. http ://dx .doi .org/10 .1371/journal .pone .0062402
13. de Calignon, A., M. Polydoro, M. Suárez-Calvet, C. William, D.H. Adamowicz, K.J. Kopeikina, R. Pitstick, N. Sahara, K.H. Ashe, G.A. Carlson, et al. 2012. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 73:685-697. http ://dx .doi .org/10 .1016/j .neuron .2011 .11 .033
14. DeMattos, R.B., K.R. Bales, M. Parsadanian, M.A. O'Dell, E.M. Foss, S.M. Paul, and D.M. Holtzman. 2002. Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81:229-236. http ://dx .doi .org/10 .1046/j .1471-4159 .2002 .00889 .x
15. Desplancq, D., D.J. King, A.D. Lawson, and A. Mountain. 1994. Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. Protein Eng. 7:1027-1033. http ://dx .doi .org/10 .1093/protein/7 .8 .1027
16. Freeman, G.B., T.P. Brown, K. Wallace, and K.R. Bales. 2012. Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice. Curr. Alzheimer Res. 9:1059-1068. http ://dx .doi .org/10 .2174/156720512803569064
17. Goedert, M., and R. Jakes. 1990. Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 9:4225-4230
18. Holmes, B.B., J.L. Furman, T.E. Mahan, T.R. Yamasaki, H. Mirbaha, W.C. Eades, L. Belaygorod, N.J. Cairns, D.M. Holtzman, and M.I. Diamond. 2014. Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl. Acad. Sci. USA. 111:E4376-E4385. http ://dx .doi .org/10 .1073/pnas .1411649111
19. Huang, L., X. Su, and H.J. Federoff. 2013. Single-chain fragment variable passive immunotherapies for neurodegenerative diseases. Int. J. Mol. Sci. 14:19109-19127. http ://dx .doi .org/10 .3390/ijms140919109
20. Jeganathan, S., M. von Bergen, E.-M. Mandelkow, and E. Mandelkow. 2008. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry. 47:10526-10539. http ://dx .doi .org/10 .1021/bi800783d
21. Johnson, K.A., A. Schultz, R.A. Betensky, J.A. Becker, J. Sepulcre, D. Rentz, E. Mormino, J. Chhatwal, R. Amariglio, K. Papp, et al. 2016. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79:110-119. http ://dx .doi .org/10 .1002/ana .24546
22. Kantor, B., T. McCown, P. Leone, and S.J. Gray. 2014. Clinical applications involving CNS gene transfer. Adv. Genet. 87:71-124
23. Lasagna-Reeves, C.A., D.L. Castillo-Carranza, U. Sengupta, M.J. Guerrero-Munoz, T. Kiritoshi, V. Neugebauer, G.R. Jackson, and R. Kayed. 2012. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci. Rep. 2:700. http ://dx .doi .org/10 .1038/srep00700
24. Lee, S.-H., C.E. Le Pichon, O. Adolfsson, V. Gafner, M. Pihlgren, H. Lin, H. Solanoy, R. Brendza, H. Ngu, O. Foreman, et al. 2016. Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Reports. 16:1690-1700. http ://dx .doi .org/10 .1016/j .celrep .2016 .06 .099
25. Lee, V.M., M. Goedert, and J.Q. Trojanowski. 2001. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:1121-1159. http ://dx .doi .org/10 .1146/annurev .neuro .24 .1 .1121
26. Nelson, P.T., I. Alafuzoff, E.H. Bigio, C. Bouras, H. Braak, N.J. Cairns, R.J. Castellani, B.J. Crain, P. Davies, K. Del Tredici, et al. 2012. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J. Neuropathol. Exp. Neurol. 71:362-381. http ://dx .doi .org/10 .1097/NEN .0b013e31825018f7
27. Nicoll, J.A.R., D. Wilkinson, C. Holmes, P. Steart, H. Markham, and R.O. Weller. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat. Med. 9:448-452. http ://dx .doi .org/10 .1038/nm840
28. Orgogozo, J.-M., S. Gilman, J.-F. Dartigues, B. Laurent, M. Puel, L.C. Kirby, P. Jouanny, B. Dubois, L. Eisner, S. Flitman, et al. 2003. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. 61:46-54. http ://dx .doi .org/10 .1212/01 .WNL .0000073623 .84147 .A8
29. Sankaranarayanan, S., D.M. Barten, L. Vana, N. Devidze, L. Yang, G. Cadelina, N. Hoque, L. DeCarr, S. Keenan, A. Lin, et al. 2015. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One. 10:e0125614. http ://dx .doi .org/10 .1371/journal .pone .0125614
30. Senior, K. 2002. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 1:3. http ://dx .doi .org/10 .1016/S1474-4422(02)00023-6
31. Sevigny, J., P. Chiao, T. Bussière, P.H. Weinreb, L. Williams, M. Maier, R. Dunstan, S. Salloway, T. Chen, Y. Ling, et al. 2016. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 537:50-56. http ://dx .doi .org/10 .1038/nature19323
32. Sheikholvaezin, A., P. Sandström, D. Eriksson, N. Norgren, K. Riklund, and T. Stigbrand. 2006. Optimizing the generation of recombinant single-chain antibodies against placental alkaline phosphatase. Hybrid. 25:181-192. http ://dx .doi .org/10 .1089/hyb .2006 .25 .181
33. Weingarten, M.D., A.H. Lockwood, S.Y. Hwo, and M.W. Kirschner. 1975. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. USA. 72:1858-1862. http ://dx .doi .org/10 .1073/pnas .72 .5 .1858
34. Witman, G.B., D.W. Cleveland, M.D. Weingarten, and M.W. Kirschner. 1976. Tubulin requires tau for growth onto microtubule initiating sites. Proc. Natl. Acad. Sci. USA. 73:4070-4074. http ://dx .doi .org/10 .1073/pnas .73 .11 .4070
35. Yamada, K., J.K. Holth, F. Liao, F.R. Stewart, T.E. Mahan, H. Jiang, J.R. Cirrito, T.K. Patel, K. Hochgräfe, E.-M. Mandelkow, and D.M. Holtzman. 2014. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211:387-393. http ://dx .doi .org/10 .1084/jem .20131685
36. Yanamandra, K., N. Kfoury, H. Jiang, T.E. Mahan, S. Ma, S.E. Maloney, D.F. Wozniak, M.I. Diamond, and D.M. Holtzman. 2013. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 80:402-414. http ://dx .doi .org/10 .1016/j .neuron .2013 .07 .046
37. Yanamandra, K., H. Jiang, T.E. Mahan, S.E. Maloney, D.F. Wozniak, M.I. Diamond, and D.M. Holtzman. 2015. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann. Clin. Transl. Neurol. 2:278-288. http ://dx .doi .org/10 .1002/acn3 .176
38. Yoshiyama, Y., M. Higuchi, B. Zhang, S.-M. Huang, N. Iwata, T.C. Saido, J. Maeda, T. Suhara, J.Q. Trojanowski, and V.M.-Y. Lee. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 53:337-351. http ://dx .doi .org/10 .1016/j .neuron .2007 .01 .010
39. Zhang, B., J. Carroll, J.Q. Trojanowski, Y. Yao, M. Iba, J.S. Potuzak, A.-M.L. Hogan, S.X. Xie, C. Ballatore, A.B. Smith III, et al. 2012. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32:3601-3611. http ://dx .doi .org/10 .1523/JNE URO SCI .4922-11 .2012